Illumina, Inc. (NASDAQ:ILMN) SVP Oene Mark Van sold 1,250 shares of the company’s stock in a transaction on Thursday, October 12th. The shares were sold at an average price of $207.21, for a total value of $259,012.50. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink.

Oene Mark Van also recently made the following trade(s):

  • On Tuesday, September 12th, Oene Mark Van sold 9,729 shares of Illumina stock. The shares were sold at an average price of $211.33, for a total value of $2,056,029.57.

Shares of Illumina, Inc. (ILMN) traded down 0.63% during midday trading on Friday, hitting $206.92. The company’s stock had a trading volume of 422,227 shares. The company has a market cap of $30.21 billion, a P/E ratio of 41.52 and a beta of 0.76. Illumina, Inc. has a 1-year low of $119.37 and a 1-year high of $214.34. The company has a 50-day moving average price of $204.49 and a 200 day moving average price of $185.71.

Illumina (NASDAQ:ILMN) last posted its quarterly earnings data on Tuesday, August 1st. The life sciences company reported $0.82 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $0.68 by $0.14. Illumina had a return on equity of 19.69% and a net margin of 30.27%. The firm had revenue of $662.00 million during the quarter, compared to analyst estimates of $642.38 million. During the same period last year, the company posted $0.86 EPS. The business’s quarterly revenue was up 10.3% on a year-over-year basis. On average, equities research analysts predict that Illumina, Inc. will post $3.65 EPS for the current year.

COPYRIGHT VIOLATION NOTICE: This news story was first posted by Watch List News and is owned by of Watch List News. If you are reading this news story on another site, it was illegally stolen and reposted in violation of United States and international copyright laws. The legal version of this news story can be read at https://www.watchlistnews.com/illumina-inc-ilmn-svp-oene-mark-van-sells-1250-shares-of-stock/1630937.html.

Several hedge funds have recently bought and sold shares of ILMN. Municipal Employees Retirement System of Michigan raised its position in shares of Illumina by 1.5% in the 1st quarter. Municipal Employees Retirement System of Michigan now owns 4,740 shares of the life sciences company’s stock worth $809,000 after acquiring an additional 70 shares in the last quarter. Teachers Advisors LLC raised its position in shares of Illumina by 60.7% in the 1st quarter. Teachers Advisors LLC now owns 384,300 shares of the life sciences company’s stock worth $65,577,000 after acquiring an additional 145,231 shares in the last quarter. Massachusetts Financial Services Co. MA bought a new position in shares of Illumina in the 1st quarter worth about $2,404,000. Global X Management Co. LLC raised its position in shares of Illumina by 30.7% in the 1st quarter. Global X Management Co. LLC now owns 1,281 shares of the life sciences company’s stock worth $219,000 after acquiring an additional 301 shares in the last quarter. Finally, Tekla Capital Management LLC increased its position in Illumina by 20.6% in the 1st quarter. Tekla Capital Management LLC now owns 297,360 shares of the life sciences company’s stock valued at $50,742,000 after buying an additional 50,800 shares in the last quarter. 93.32% of the stock is owned by hedge funds and other institutional investors.

ILMN has been the topic of several research reports. Vetr lowered Illumina from a “strong-buy” rating to a “buy” rating and set a $197.84 price target on the stock. in a research note on Wednesday, June 21st. Zacks Investment Research raised Illumina from a “hold” rating to a “buy” rating and set a $195.00 price target on the stock in a research note on Thursday, July 27th. Canaccord Genuity raised Illumina from a “hold” rating to a “buy” rating and upped their price target for the company from $170.00 to $215.00 in a research note on Monday, August 7th. Argus upped their price target on Illumina from $205.00 to $235.00 and gave the company a “buy” rating in a research note on Wednesday, September 13th. Finally, First Analysis raised Illumina from an “underweight” rating to an “equal weight” rating and set a $176.00 price target on the stock in a research note on Wednesday, August 2nd. Three investment analysts have rated the stock with a sell rating, eight have issued a hold rating and eleven have given a buy rating to the company. Illumina has an average rating of “Hold” and a consensus target price of $190.50.

About Illumina

Illumina, Inc (Illumina) is a provider of sequencing- and array-based solutions for genetic analysis. The Company operates through two segments: Core Illumina and the consolidated variable interest entities (VIEs), which include the activities of GRAIL, Inc (GRAIL) and Helix Holdings I, LLC (Helix). Core Illumina consists of its core operations.

Insider Buying and Selling by Quarter for Illumina (NASDAQ:ILMN)

Receive News & Ratings for Illumina Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.